Scientific congress for the therapeutics sector
Bringing together five streams of content over two days, the 2014 ARCS Scientific Congress for professional developers in therapeutics promises to be an event not to miss.
.jpg)
Sessions topics include:
- clinical monitoring and project management
- clinical coordination
- research governance (including ethics and site assessment)
- academic-/investigator-initiated research
- workplace management and personal effectiveness
- medical information
- pharmacovigilance
- medical affairs
The congress will provide up-to-date accounts on what’s happening in the professional landscape, particularly regarding research governance for those working in clinical research.
The opportunity for professional development will also be available at the congress as well as great opportunities for networking with colleagues, industry experts, opinion leaders and suppliers.
Some of the speaker highlights include:
- Ms Christine Pierre, CEO and Founder of US site management company RxTrials, and the Founder and President of the Society for Clinical Research Sites
- Ms Julia Evans, Technology and Services Industries Branch, Department of Industry
- Dr Tim Dyke, NHMRC
- Ms Janet Anderson, First Assistant Secretary, Acute Care Division, Department of Health and Ageing
- Dr Dalvir Gill, CEO, TransCelerate Biopharma
The congress will be held at the Royal Randwick Turf Club, Sydney, 3-4 June 2014.
Registrations are open. For more information go to the congress website.

ARCS Australia, previously the Association of Regulatory and Clinical Scientists, is a not-for-profit professional development association representing people involved in the development of therapeutic products. Founded in 1984, ARCS provides education, information and training to industry and non-industry personnel, irrespective of membership. ARCS educational events are open to members and non-members
MV Hondius passengers return to Australia under strict infection control measures
The Australian CDC has provided an update on hantavirus risk to Australians and infection...
$96m RNA Research and Manufacturing Facility opens in NSW
The new 4500 sqm RNA Research and Manufacturing Facility within the Macquarie University...
Cartherics and Catalent announce enhanced partnership
To support immune cell therapy products for the treatment of cancer and endometriosis, Australian...
